Healthcare / BiotechnologyLSE
$70.00
+4.00 (+6.06%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-6.0M · quality 67.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
44/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$26M
P/E
35.0x
↑EV/EBITDA
2260.4x
↑ROE
10.3%
↑Gross Margin
73.9%
↑Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-10.7%
FCF CAGR
—
FCF margin
-143.6%
FCF / Net income
-3.71x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.7M · net income $664000.0 · FCF $-2.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.7M | $1.7M | $1.6M | $4.6M | $2.4M |
| Net Income | $664000.00 | $664000.00 | $-10.2M | $-8.6M | $-9.3M |
| EBITDA | $1.2M | $1.2M | $-4.7M | $-8.4M | $-10.1M |
| EPS | 0.02 | 0.02 | -0.31 | -0.00 | -0.32 |
| Gross Margin | 73.9% | 73.9% | 55.9% | 27.4% | — |
| Operating Margin | -236.0% | -236.0% | -315.0% | -200.6% | -437.5% |
| Net Margin | 38.7% | 38.7% | -623.0% | -187.1% | -385.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.04 | 0.04 | 0.02 |
| Current Ratio | 4.78 | 4.78 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-2.5M | $-2.5M | $-9.3M | $-6.0M | $-11.1M |
| Returns | |||||
| ROE | 10.3% | 10.3% | -191.4% | -89.8% | -53.1% |
| Valuation | |||||
| P/E | 35.00 | 35.00 | — | — | — |
| EV/EBITDA | 2260.43 | 2260.43 | — | — | — |
| P/B | 427.74 | 427.74 | 462.62 | 559.29 | 397.86 |
| Growth & Yield | |||||
| Revenue Growth | 4.3% | 4.3% | -64.1% | 90.3% | — |
| EPS Growth | 106.5% | 106.5% | -10971.4% | 99.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
577.2%
EPS terminal req.
$6.21
Spread vs growth
-470.8%
5Y implied EPS CAGR
227.3%
EPS terminal req.
$7.52
Spread vs growth
-120.9%
10Y implied EPS CAGR
89.8%
EPS terminal req.
$12.10
Spread vs growth
16.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+60.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.31 → 0.02
Residual
+60.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.